Global /United States /Healthcare /Medical Devices /950130

Access Bio, Inc.

950130

• KRX: 950130 • Delayed

3,415KRW -2%

2.25 USD

As of 14 June 2026, Access Bio, Inc. has a market cap of $80.6M USD, ranking #27078 globally and #4113 in the United States. It ranks #2429 in the Healthcare sector, and #496 in the Medical Devices industry.

Global Rank

27078

Country Rank

4113

Sector Rank

2429

Industry Rank

496

Key Stats

Market Cap

$80.6MUSD

122.58B KRW

Enterprise Value

-$155.62MUSD

-236.27B KRW

Revenue (TTM)

$20.55MUSD

31.26B KRW

EBITDA (TTM)

-$30.98MUSD

-47.03B KRW

Net Income (TTM)

-$54.0MUSD

-82.12B KRW

EBITDA Margin

-150%

Profit Margin

-263%

PS Ratio

3.9

PB Ratio

0.2

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Medical Devices

CEO

Young-Ho Choi open_in_new

Employees

101

Founded

2002

Website

accessbio.net open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-2%	-4.6%	21%	-11%	-15%	-9.3%	-32%	-64%	-91%

News

Markets

Exchange	Ticker	Price	Quotes
Korea Exchange (KRX) MIC: XKRX PRIMARY	950130 Access Bio Inc Korean Depository Receipts ISIN: KR8840090003 Shares Out.: Shares Outstanding: 35.174M¹ Shares Float: 26.623M² TV: TradingView: KRX: 950130 SA: Stock Analysis: KRX: 950130 YF: Yahoo Finance: 950130.KS GF: Google Finance: KRX: 950130 BA: Barron's: 950130 MS: Morningstar: XKRX: 950130	3,415 KRW	TV: TradingView: KRX: 950130 SA: Stock Analysis: KRX: 950130 YF: Yahoo Finance: 950130.KS GF: Google Finance: KRX: 950130 BA: Barron's: 950130 MS: Morningstar: XKRX: 950130

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Access Bio, Inc.

Access Bio, Inc. engages in the research, development, and manufacture of in vitro rapid diagnostic tests, immunochemical diagnostics, biosensors, and molecular diagnostic products worldwide. The company provides Covid-19 detection kits, which are tests for assessing the current or past presence of SARS-CoV-2.; rapid diagnostic tests, suitable for preliminary diagnosis or emergency medical screening in medical facilities with limited resources; analyzers, designed to measure different chemicals and other characteristics in biological samples; and molecular diagnostic solutions used in analyzing biological markers in the genome and proteome. It offers its products under CareStart, CareUS, CareSURE, and CareGENE brand names. The company was incorporated in 2002 and is headquartered in Somerset, New Jersey.

Similar Companies

Industry: Medical Devices (United States)

Name	Market Cap (USD) diff.	PE	Country
Thermo Fisher Scientific Inc. NYSE: TMO	$173.27B 215K%	25.8	United States
Intuitive Surgical, Inc. NASDAQ: ISRG	$160.73B 199K%	56.7	United States
Abbott Laboratories NYSE: ABT	$159.07B 197K%	25.6	United States
Danaher Corp. NYSE: DHR	$126.55B 157K%	34.7	United States
Stryker Corp. NYSE: SYK	$120.69B 150K%	38.3	United States
Boston Scientific Corp. NYSE: BSX	$84.93B 105K%	24.5	United States

Industry: Medical Devices (Global)

Name	Market Cap (USD) diff.	PE	Country
Medtronic plc NYSE: MDT	$101.9B 126K%	22.2	Ireland
EssilorLuxottica Société anonyme EPA: EL	$97.46B 84.32B EUR 121K%	36.7	France
HOYA Corp. TSE: 7741	$61.41B 9.83T JPY 76K%	40.0	Japan
Siemens Healthineers AG XETRA: SHL	$45.47B 39.34B EUR 56K%	18.7	Germany
Alcon Inc. SIX: ALC	$36.38B 28.99B CHF 45K%	37.9	Switzerland
Shenzhen Mindray Bio-Medical Electronics Co., Ltd. SHE: 300760	$30.06B 203.66B CNY 37K%	26.0	China

chevron_leftBack